Navigation Links
At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed)

WASHINGTON, DC, June 11, 2007 /PRNewswire-FirstCall/ - Paul S. Aisen, M.D., Professor of Neurology and Medicine at Georgetown University Medical Center, and principal investigator in the United States of Neurochem Inc.'s North American Phase III clinical trial for tramiprosate (ALZHEMED(TM)) will present today an update on Neurochem's investigational product candidate for the treatment of Alzheimer's disease (AD). The presentation by Dr. Aisen will take place at the Intervention and Treatment Session, scheduled from 2:30 - 4:30 P.M. (ET), at the Alzheimer's Association International Conference on Prevention of Dementia in Washington, DC. In his presentation entitled, A Phase III Study of the Efficacy, Safety and Disease Modification Effect of Tramiprosate in Mild-to-Moderate Alzheimer's Disease, Dr. Aisen will review the Phase III clinical trial and provide an update.

Neurochem announced in April 2007 that an adjustment to the initial statistical model, as set out in the statistical plan, would be necessary to provide accurate results. The procedure to arrive at a reliable model involves a detailed analysis of potential confounding factors, and Dr. Aisen will present on the progress to date. In addition, Dr. Aisen will provide an update on the progress in the analysis of the Phase III clinical trial primary endpoint data. Some preliminary descriptive data shows numerical differences in favor of tramiprosate (ALZHEMED(TM)) on the primary clinical endpoint and also shows differences between groups on the primary disease modification endpoint as measured by magnetic resonance imaging (MRI). However, work regarding the adjustment of the statistical model is ongoing and, therefore results of the Phase III clinical trial cannot be derived from the preliminary data nor can statistical significance be assigned at this time. Accordingly, no predictions or conclusions can yet be made regarding the outcome of the Phase III study.






Page: 1 2 3 4

Related medicine technology :

1. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
2. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
3. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
6. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
7. Clinical Update - Debio 9902 (ZT-1) for Alzheimers Disease
8. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
9. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
10. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease
11. Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimers Drug
Post Your Comments:
(Date:10/20/2014)... de octubre de 2014  PneumRx, Inc. ( ... la pulmonología intervencional, anunció hoy la conclusión de ... meses antes de lo programado. El Estudio Clínico RENEW ... de investigación (IDE) aprobada por la FDA (Administración ... espiral de reducción de volumen pulmonar PneumRx RePneu, ...
(Date:10/20/2014)... , Oct. 20, 2014  ResMed (NYSE: ... the ResMed Data Exchange program, a comprehensive suite ... equipment (HME) and other health care providers. ... access to critical patient information. It integrates valuable ... and U-Sleep™ patient management platforms with customers, in-house ...
(Date:10/20/2014)... 20, 2014  AnaptysBio, Inc., a leader in ... announced the appointment of Marco Londei , ... lead the preclinical and clinical development of AnaptysBio,s ... pleased to welcome Dr. Londei to AnaptysBio,s executive ... and Chief Executive Officer of AnaptysBio. "Dr. Londei,s ...
Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3ResMed Launches ResMed Data Exchange 2AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2
... REYKJAVIK, Iceland, July 1 The ... several new common,single-letter variants in the sequence of the human ... a multinational consortium of scientists,led by a team from deCODE ... 50,000 patients and control participants from fourteen countries.,It is published ...
... announces that it has reached the halfway mark (1,600 patients) ... G auging R esponsiveness with A V erifyNow(R) ... nd S afety). The trial is specifically designed ... for patients who are poor responders to clopidogrel (Plavix(R)). ...
Cached Medicine Technology:deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 2deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 3deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 4deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 5Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled 2
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute is offering ... a damaged mitral valve as the heart continues to ... Abbott Vascular , is designed to treat degenerative ... which the heart’s mitral valve leaflets fail to close ... left ventricle into the left atrium. The heart must ...
(Date:10/20/2014)... 2014 ASCNYC (ascnyc.org) is a ... New Yorkers living with HIV/AIDS and other chronic ... recovery and self-sufficiency. Each year, ASCNYC spotlights selected ... through their tireless efforts. , Savills Studley ... has been selected as this year’s honoree for ...
(Date:10/20/2014)... T.E.N., a technology and information ... that William H. Murray, renowned author and industry ... Leadership Award winner. Presented annually, the ISE® Luminary ... leader and industry practitioner for his or her ... information security industry. , Formerly with IBM, Murray ...
(Date:10/20/2014)... D.C. (PRWEB) October 20, 2014 Zereana Jess-Huff, ... crowned Mrs. Maryland 2014 on a platform to think outside ... scars, and uses her position to raise awareness about women’s ... awareness for breast cancer. You say the color pink and ... I know for a fact that it has not been ...
(Date:10/20/2014)... Kennewick, WA (PRWEB) October 20, 2014 ... new workflow management software application. The new module ... ensure patients receive full life-cycle quality care. , This ... to others within their practice, attach a to-do item ... see fit, and even set up reoccurring reminders for ...
Breaking Medicine News(10 mins):Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:My Clients Plus Announces New Workflow Management Software 2
... IQ for HealthVault Empowers Patients to Orchestrate Health ... ... Kryptiq, the leading provider,of next generation healthcare connectivity solutions, ... offices,and patients using Microsoft(R) HealthVault(TM), at the 2008 HIMSS,(Healthcare Information ...
... Calif., Feb. 25 Hyperion,Therapeutics, Inc. today announced ... Phase 2 clinical trial of AMMONUL(R) (sodium phenylacetate ... III or IV hepatic,encephalopathy (HE). The randomized, double-blind ... of AMMONUL versus standard of care in,hospitalized adults. ...
... CHARLOTTE, N.C., Feb. 25 MedCath Corporation,(Nasdaq: MDTH ... at the Raymond James 29th Annual Institutional Investors,Conference held ... Orlando,Fla., MedCath,s senior management will give its presentation ... will be web cast live over the Internet,via MedCath,s ...
... 25 Omron Healthcare, Inc. has,announced Bob ... officer. With,an extensive background in sales, Kondraske ... profit growth in their mainstay business,categories: blood ... medical. Kondraske,s experience as a proven,business leader ...
... Va., Feb. 25 Meddius, an emerging,provider ... integration technology and professional services to assist ... system,which provides hospitals with a Web-based, automated ... associated infections (HAIs). The announcement,was made today ...
... enhanced to support multifaceted hospital, environments; provide more secure ... ... Feb. 25 HIMSS ,08 -- Omnicell,Inc. (Nasdaq: ... acute,healthcare facilities, today introduced its OptiFlex(TM) SS 9.0 supply,chain ...
Cached Medicine News:Health News:Kryptiq and Microsoft to Showcase Unprecedented Connectivity Between Consumers and Their Doctors at HIMSS '08 2Health News:Kryptiq and Microsoft to Showcase Unprecedented Connectivity Between Consumers and Their Doctors at HIMSS '08 3Health News:Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy 2Health News:Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy 3Health News:Omron Healthcare Names New Chief Operating Officer Bob Kondraske 2Health News:Meddius Signs Agreement to Deliver an Integration Platform for Premier's SafetySurveillor(TM) 2Health News:Hospital Environments Increase Staff Efficiency and Patient Safety With Omnicell OptiFlex(TM) SS 9.0 2Health News:Hospital Environments Increase Staff Efficiency and Patient Safety With Omnicell OptiFlex(TM) SS 9.0 3
... The LT-Cage device ... balance with significantly less ... endplates. Medtronic Sofamor Danek's ... designed to easily and ...
3D Cranial is the most widely used surgical navigation software. Navigate with confidence and ease with displayed Zone of Accuracy and several fully automated features. 3D Cranial offers seamless int...
Designed for the effective positioning of patients during spinal surgery, the frame gives the surgeon a remarkably simple and versatile surgical tool....
Adjust-A-Tip cautery....
Medicine Products: